Multidrug resistance (MDR) is one of conventional cancer chemotherapy's limitations. Our
group previously synthesized a series of quinoline-based compounds in an attempt to …

Multidrug resistance (MDR) mediated by the over expression of drug efflux protein P-
glycoprotein (P-gp) is one of the major impediments to successful treatment of cancer. P-gp …

Multidrug resistance (MDR) limits the therapeutic effect of conventional chemotherapeutic
agents as well as novel targeted anticancer drugs. An important mechanism of MDR is the …

Multidrug resistance (MDR) is one of the main obstacles of clinical chemotherapy. A great
deal of research shows that the occurrence of drug resistance in various malignant tumors is …

The overexpression of P-glycoprotein (P-gp) on the surface of tumor cells causes multidrug
resistance (MDR). This protein acts as an energy-dependent drug efflux pump reducing the …

Overexpression of P-glycoprotein (P-gp) is one of the major obstacles to successful cancer
chemotherapy. In this study, we examined the ability of 4-chloro-N-(3-((E)-3-(4-hydroxy-3 …

Background: The typical transporter protein, P-glycoprotein (P-gp), has been proven to be
associated with multidrug resistance (MDR). Pyxinol and 24S-Pyxinol amino acid ester …

Multidrug resistance (MDR) to chemotherapeutic drugs is the main cause of chemotherapy
failure in cancer treatment, and it generally results from expression of ATP-dependent efflux …

Multidrug resistance (MDR) is still the main barrier to attaining effective results with
chemotherapy. Discovery of new chemo‐reversal agents is needed to overcome MDR. Our …

Overexpression of P-glycoprotein (Pgp) is associated with multidrug resistance (MDR) of
tumor cells to a number of chemotherapeutic drugs. Pgp inhibitors have been shown to …